Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.

• Main Authors: Romain Guery (Author), Benoit Henry (Author), Guillaume Martin-Blondel (Author), Claire Rouzaud (Author), Florence Cordoliani (Author), Gundel Harms (Author), Jean-Pierre Gangneux (Author), Françoise Foulet (Author), Emmanuelle Bourrat (Author), Michel Baccard (Author), Gloria Morizot (Author), Paul-Henri Consigny (Author), Antoine Berry (Author), Johannes Blum (Author), Olivier Lortholary (Author), Pierre Buffet (Author), French Cutaneous Leishmaniasis Study group & the LeishMan network (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefit in this indication.We conducted a retrospective analysis of data from a French centralized referral treatment program...